STK11

Across TCGA pan-cancer cohorts, STK11 Mutation is linked to patient survival in 11 of 34 cancer types, making it a survival-associated STK11 data layer compared with 26 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher STK11 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated STK11 expression acts as an unfavorable survival marker.

CESC, STAD, and LIHC are the cancer types where STK11 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CESC	OS	Median	II,III,IV	0.230	0.770	<.001	26	view →
STAD	OS	Median	All	0.064	0.670	<.001	24	view →
LIHC	OS	Median	All	0.126	0.786	<.001	15	view →
SARC	DFS	Median	All	0.121	0.611	.041	6	view →
ACC	OS	Median	All	0.118	0.624	.038	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
COAD	DFS	Median	All	0.426	0.795	.020	4	view →
LUAD	DFS	Median	All	0.620	0.782	.022	3	view →
SKCM	DFS	Median	III,IV	0.088	0.597	.021	3	view →
LUSC	OS	Median	All	0.392	0.727	.040	2	view →

Pink = unfavorable, green = favorable. Showing the 11 strongest of 11 lineages.

STK11–CESC (OS)

Open the CESC breakdown →